India CDSCO Says Far Short Of Necessary Drug, Device Inspectors
This article was originally published in PharmAsia News
India's Central Drug Standard Control Organization has less than one-third of the drug inspectors it needs, so the agency plans to begin a drive to recruit and train more
You may also be interested in...
Cipla is celebrating an “important milestone” for the company after the successful completion of a Phase III clinical trial comparing its proposed Advair generic with GSK’s brand in the US. Management has cautioned that approval will be a way off yet, however.
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.